Cargando…

Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy

BACKGROUND: Although chimeric antigen receptor (CAR)-T cell therapy has been remarkably successful for haematological malignancies, its efficacy against solid tumors is limited. The combination of CAR-T cell therapy with immune checkpoint inhibitors (CPIs), such as PD-1, PD-L1, and CTLA-4 antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yajun, Wang, Pei, Wang, Tengjiao, Fang, Yuan, Ding, Yongmei, Qian, Qijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890961/ https://www.ncbi.nlm.nih.gov/pubmed/33602263 http://dx.doi.org/10.1186/s12967-021-02750-4

Ejemplares similares

Agonistic CD40 Antibodies in Cancer Treatment
por: Djureinovic, Dijana, et al.
Publicado: (2021)

Evaluation of Nonviral piggyBac and lentiviral Vector in Functions of CD19chimeric Antigen Receptor T Cells and Their Antitumor Activity for CD19(+) Tumor Cells
por: Lin, Zhicai, et al.
Publicado: (2022)

CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches
por: Argiriadi, Maria A., et al.
Publicado: (2019)

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
por: Salomon, Ran, et al.
Publicado: (2022)

Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment
por: van Hooren, Luuk, et al.
Publicado: (2016)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells
por: Hombach, Andreas A., et al.
Publicado: (2012)

Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies
por: Li, Da-Ke, et al.
Publicado: (2020)

Engineering and Design of Chimeric Antigen Receptors
por: Guedan, Sonia, et al.
Publicado: (2018)

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
por: Hägerbrand, Karin, et al.
Publicado: (2022)

Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells
por: Yang, Liu, et al.
Publicado: (2021)

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013)

Pre-clinical development of the human CD40 agonistic antibody ADC-1013
por: Norlén, Per, et al.
Publicado: (2015)

Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells
por: Dixon, Brianne N., et al.
Publicado: (2020)

Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells
por: SAKAI, Osamu, et al.
Publicado: (2021)

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
por: Wang, Yan, et al.
Publicado: (2023)

Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
por: Thomas, Lawrence J, et al.
Publicado: (2014)

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
por: Otáhal, Pavel, et al.
Publicado: (2015)

Engineering better chimeric antigen receptor T cells
por: Zhang, Hao, et al.
Publicado: (2020)

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy
por: Rataj, Felicitas, et al.
Publicado: (2018)

Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1
por: Cui, Tengjiao, et al.
Publicado: (2018)

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
por: Qin, Jim S., et al.
Publicado: (2020)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2015)

Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2016)

Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo
por: Sommermeyer, Daniel, et al.
Publicado: (2015)

Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma
por: Ogunnaike, Edikan A., et al.
Publicado: (2021)

A Fast and Sensitive Luciferase-based Assay for Antibody Engineering and Design of Chimeric Antigen Receptors
por: Natarajan, Venkatesh, et al.
Publicado: (2020)

Engineering chimeric antigen receptor T cells for solid tumour therapy
por: Liu, Longwei, et al.
Publicado: (2022)

The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy
por: Frankish, Jamie, et al.
Publicado: (2023)

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
por: Cartellieri, Marc, et al.
Publicado: (2010)

Engineering chimeric antigen receptor-T cells for cancer treatment
por: Ye, Baixin, et al.
Publicado: (2018)

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
por: Sandin, Linda C, et al.
Publicado: (2014)

CD40 agonist-induced IL-12p40 potentiates hepatotoxicity
por: Bonnans, Caroline, et al.
Publicado: (2020)

CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo
por: Tang, Xiaojun, et al.
Publicado: (2019)

Programmed death‐ligand 1 expression on CD22‐specific chimeric antigen receptor‐modified T cells weakens antitumor potential
por: Liu, Jie, et al.
Publicado: (2022)

Concepts for agonistic targeting of CD40 in immuno-oncology
por: Richards, David M., et al.
Publicado: (2019)

OX40‐targeted immune agonist antibodies induce potent antitumor immune responses without inducing liver damage in mice
por: Tee, Yee C., et al.
Publicado: (2021)

Apoptosis of CD19(+) chimeric antigen receptor T cells after treatment with chemotherapeutic agents
por: Yi, Wenfang, et al.
Publicado: (2018)

Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells
por: Morita, Daisuke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fgapd2b26n0nl3994m6o90t2c0